Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Saw this stock on my otcbb screen. Looks interesting. Has the company ever talked about how quickly they will be able to generate revenue once they start harvesting adult stem cells. Are they looking to turn around and sell these to labs and entities working on therapies, or is the business model more in line with have a "bank" that an individual can use should they become injured and need therapy.
Just trying to figure out how big a deal the May 10th "harvest" event will be?
Thanks fo any info.
Murocman
Not sure this answers your question, but I just bought today with no problem on ETrade.
Murocman
Have to call ETrade to buy shares. Anyone else have the same constraint with another broker?
Thanks,
Murocman
Here's how EIG makes it's money:
Management Company Energy Program
Helping management companies gain a competitive advantage.
You can assist your clients in taking advantage of special rebates that can be up to triple the standard rebate through utilities, and reducing energy cost 10-30% beyond the conventional type energy projects that have likely already been completed. This can be a valuable tool for you to maintain clients and attract new clients..
EIG can guide your clients to take advantage of the latest advances in emerging energy efficiency technology and of these special rebate programs. Paybacks typically range from 12-36 months. Projects can be completed with no cash outlay. EIG coordinates the entire program to free you from any major resource commitment.
The property management company energy program.
It is clear that energy is a major concern of your clients. Property management companies can provide a valuable benefit by communicating emerging energy efficient technology and special rebate opportunities to these clients.
EIG prepares email or direct mail communications to property managers and clients.
EIG prepares website material for energy savings and rebate opportunities.
EIG develops energy news articles for newsletters.
EIG introduces the energy opportunity at property manager meetings.
EIG works with the property managers to identify new technology opportunities and guide completion of projects in your client facilities.
The simple 3-step EIG process to assist you and your clients.
EIG identifies opportunities to use new technologies in clients' facilities
EIG prepares an Opportunity Report of potential savings from these technologies, available rebates, and financial options.
EIG coordinates projects from inception through completion, securing rebates, arranging financing, documenting savings, commissioning and retro-commissioning.
EIG Compensation
There is no fee to a company for EIG services. EIG receives a special level of compensation from manufacturers that contract with EIG to expand their product's visibility in the market.
Based on the above, it sounds like Axis must be paying EIG some percentage of the ballast sales. The question is how much?
GLTA,
Murocman
EPIX Pharmaceuticals Announces Positive Results From Re-Read of Vasovist(R) Phase 3 Images
Wednesday April 23, 4:01 pm ET
Company to Resubmit New Drug Application Mid-2008
Management To Host Conference Call To Discuss Results April 24, 2008 at 10:00 A.M. EDT
LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX - News), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced today it has achieved positive results from the blinded, independent re-read of images of its novel blood pool magnetic resonance angiographic (MRA) agent, Vasovist (gadofosveset trisodium). In the re-read of images obtained from previous phase 3 studies, EPIX met all pre-specified endpoints prospectively agreed to with the U.S. Food and Drug Administration (FDA). EPIX plans to resubmit a New Drug Application (NDA) to the FDA for Vasovist in mid-2008. Vasovist is currently approved for marketing in 33 countries.
ADVERTISEMENT
There are currently no contrast agents approved in the United States for use with MRA, a non-invasive modality for imaging blood vessels. However, it is estimated that approximately 1.5 million MRAs will be conducted in the United States during 2008 using gadolinium-based products.
“We believe these positive results confirm the efficacy upon which the NDA was based and allow us to move forward with our strategy of achieving U.S. regulatory approval,” said Andrew Uprichard, M.D., president and head of research and development at EPIX. “We worked closely with the FDA to design the protocol and statistical analysis plan for the re-read of these images and look forward to continuing our work with the FDA to bring Vasovist to market in the United States.”
“We remain focused on monetizing our Vasovist asset in the near- to mid-term and these positive results are a significant milestone towards achieving this goal,” added Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX. “We believe these positive results position us well for FDA approval and that our product, if approved, will serve a large and unmet need in the U.S. MRA market. We are hopeful that we will be able to work with the FDA to achieve approval for Vasovist by the end of 2008. Currently, there are no MRA imaging agents approved in the United States, however, market research suggests that unapproved gadolinium-based agents are used for MRA. We are confident that Vasovist has distinguishing characteristics that will be appealing to physicians and patients for this indication. Based upon these market dynamics, we believe we will be able to utilize this asset to support the multiple product opportunities in our clinical pipeline. We remain on track with our plans to initiate our Phase 2b clinical program for PRX-03140 in Alzheimer’s disease, partnered with GlaxoSmithKline (GSK) and the Phase 2b right-heart catheter study in pulmonary hypertension with chronic obstructive pulmonary disease. We also continue to engage in strong partnerships with GSK, Amgen and Cystic Fibrosis Foundation Therapeutics involving several of our early stage programs and look forward to continuing to achieve milestones in these programs.”
Conference Call
EPIX will host a conference call and a live webcast to discuss the positive results from the independent re-read of images of its novel blood pool magnetic resonance angiographic (MRA) agent, Vasovist at 10:00 a.m. (EDT) tomorrow, Thursday, April 24, 2008. The call can be accessed by dialing 1-866-314-5050 (domestic) or 1-617-213-8051 (international) five minutes prior to the start time and providing the passcode 35410110. The live webcast can be accessed by visiting the investor relations section of the EPIX website at http://investor.epixpharma.com. A replay of the call will be available on the EPIX website approximately two hours after completion of the call and will be archived for 30 days. The replay may be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international) and using the passcode 11785733.
About Vasovist®
Vasovist is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system through magnetic resonance angiography imaging (MRA). Vasovist has been approved for marketing in 33 countries, including, among others, all 27 member states of the European Union, Switzerland, Turkey, Australia and Canada. The initially approved indication for Vasovist in the EU, Canada and Australia is the use in MRA imaging of the abdominal and limb vessels. The Turkish and Swiss authorities granted a whole body MRA indication. The marketing rights to Vasovist are held by Bayer Schering Pharma in Europe and by Bayer HealthCare Pharmaceuticals in the United States and Canada. Both companies are part of Bayer AG. Vasovist is currently marketed in Canada and 18 European countries, including, among others, Germany, the Netherlands, Italy, all Nordic countries, United Kingdom, and Switzerland.
About EPIX
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics and Bayer Schering Pharma. For more information, please visit the company’s website at www.epixpharma.com.
Thinking about jumping in here. Looking for any thoughts anyone has regarding the significance of the AH PR today.
Thanks,
Murocman
Meeting should be wrapping up in the next couple minutes. Hoping to see a P/R.....or at least some buying.
GLTA,
Murocman
My gut feel is that today's PR is a set up for some more specific, quantitative news tomorrow such as more details about Ernst & Young, contracts and their operations.
If they do this right (like a fully-listed company would) I'd expect to see a PR before the investor meeting starts.
That would tell me that they are starting to act and operate like a mature company that wants to move to a higher exchange.
If they don't issue a PR but, but spout non-PR'ed information/make unsubstantiated claims at the investor meeting, then it's more of the same shenanigans as in the past IMO.
Hope we see something tomorrow in the AM. GLTA,
Murocman
For you chartists out there, this stock has formed a nice cup-w/handle base. Any breakout above $1.46 on strong volume would be a significant buy signal from a technical standpoint.
GLTA,
Murocman
Looking for some good price strength as we head into the next 10Q for the first quarter in a month. Any news of business expansion between now and then will be icing on the cake. Either way, I'm thinking we'll be off to the races by the end of May. Insiders would not have bought the number of shares they did/exercised options if they did not have confidence in where the company was going in the near-term.
GLTA,
Murocman
CDTR Earnings PR out After the Bell Last Night
Increased Revenues and Improved Performance Provide Foundation for Continued Growth in 2008
HONG KONG--(MARKET WIRE)--Apr 16, 2008 -- Cardtrend International Inc. (OTC BB:CDTR.OB - News) ("Cardtrend") filed on April 15th its 10KSB for 2007 which included its audited financial statements for the year ended December 31, 2007.
ADVERTISEMENT
Revenues in 2007 increased to over $1,727,000 million or about five times 2006 revenues, which were $346,700. Gross profit in 2007 increased to more than $419,000 from $135,000 in 2006 -- about 3 times. Over the same period operating costs were reduced from $4.44 million in 2006 to $3.12 million in 2007, a reduction of about 30%.
KK Ng, CEO of Cardtrend said: "Our 2007 audited results show that we made important progress during a year in which Cardtrend underwent a number of major transitions in accordance to the new strategic direction that was set out in the summer of 2006. It encourages us to continue our efforts to grow in 2008 and create value for our shareholders. We are targeting 2008 to be a year of significant progress."
CDTR Earnings PR After the Bell Last Night
Increased Revenues and Improved Performance Provide Foundation for Continued Growth in 2008
HONG KONG--(MARKET WIRE)--Apr 16, 2008 -- Cardtrend International Inc. (OTC BB:CDTR.OB - News) ("Cardtrend") filed on April 15th its 10KSB for 2007 which included its audited financial statements for the year ended December 31, 2007.
ADVERTISEMENT
Revenues in 2007 increased to over $1,727,000 million or about five times 2006 revenues, which were $346,700. Gross profit in 2007 increased to more than $419,000 from $135,000 in 2006 -- about 3 times. Over the same period operating costs were reduced from $4.44 million in 2006 to $3.12 million in 2007, a reduction of about 30%.
KK Ng, CEO of Cardtrend said: "Our 2007 audited results show that we made important progress during a year in which Cardtrend underwent a number of major transitions in accordance to the new strategic direction that was set out in the summer of 2006. It encourages us to continue our efforts to grow in 2008 and create value for our shareholders. We are targeting 2008 to be a year of significant progress."
Thoughts on Earnings
Bottom Line upfront: I like the direction this company is headed.
All of their numbers seem to be heading in the right direction. If growth were to continue at the current rate, they could be profitable for 2008.
I was a little disappointed they didn't offer any forward growth estimates. That said, they have demographics on their side in Asia, and I'd expect them to continue to make solid progress. I plan to hold at least for another month until we get the Q1 10Q and will also be looking for some more insider buying at current levels as a sign management is confident in their business.
Hopefully, the PR gets some action going tomorrow, although I don't think this is going to be a get rich quick play. I'd be happy with a steady rise towards $0.10 as we get towards the next earnings report, which would set us up for a nice pop into the $0.20-0.25 range if revenues and earnings continue to accelerate in Q1.
GLTA,
Murocman
10K filed after the market close. There is a lot of information and it will take awhile to get through everything. Hopefully they will put out a PR tomorrow. In summary, revenues were way up and net loss was down to $0.06 from $0.13 the year prior. It probably isn't going to run straight to $0.25 per share on this report, but I think it could easily see $0.10 with a PR that emphasizes future growth and improved profitability.
GLTA,
Murocman
Have excerpted operations info below:
Results of Operations
Full Year Ended December 31, 2007 Compared to Full Year Ended December 31, 2006
Revenue and Operating Expenses
Net revenue for the Company’s Processing Business Unit totaled $748,465 for the year ended December 31, 2007 as compared to $188,251 for the year ended December 31, 2006, an increase of $560,214 or 298%. The increase was primarily resulted from net revenue of $644,856 generated by the Company’s new subsidiary, Cardtrend Systems. The corresponding cost of sales was $344,239 for the year ended December 31, 2007 and $55,798 for the same corresponding period in 2006. Gross margin for the year ended December 31, 2007 was approximately 54%, while gross margin for the same corresponding period in 2006 was approximately 70%. The gross margin was lower because the effect of inclusion of lower gross margin revenue from Cardtrend Systems which is within the expectation of the Company.
Net revenue for the Company’s Prepaid Business Unit totaled $978,927 for the year ended December 31, 2007 as compared to $158,487 for the year ended December 31, 2006. This revenue was generated from the Company’s two subsidiaries in Malaysia. The Company did not have Prepaid Business Unit until December 1, 2006. The corresponding costs of sales and discounts given to the Company’s dealers totaled $963,342 for the year ended December 31, 2007 as compared to $155,885 for the year ended December 31, 2006. Gross profit for the year ended December 31, 2007 was $15,585 as compared to $2,602 for the year ended December 31, 2006, giving rise to a gross margin of about 1.59% and 1.64%, respectively.
The Company did not record any revenue or income from the Cards Business Division for the year ended December 31, 2007 and year ended December 31, 2006 as there were no dividends received from the Company’s associated companies in Malaysia, in each of which the Company owns 20% equity interest of these associated companies.
On a consolidated basis, the Company’s net revenue for the Company for the year ended December 31, 2007 totaled $1,727,392, as compared to $346,738 for the year ended December 31, 2006, an increase of about 398%. The corresponding total costs of sales were $1,307,581 as compared to $211,683 for the same corresponding period in 2006, an increase of about 518%. The total gross profit recorded by the Company was $419,811 for the year ended December 31, 2007 as compared to $135,055 for the year the year ended December 31, 2006, an increase of about 211%.
The increases on a consolidated basis were due to principally by the inclusion of Cardtrend Systems’ and other Malaysian subsidiaries’ revenues for the entire 12 months (as compared to two months for 2006) following the acquisitions. This additional net revenue from Cardtrend Systems and other Malaysian subsidiaries totaled $1,612,880, as compared to $275,888 in 2006. Revenues not related to the businesses acquired in 2006 totaled $114,512, as compared to $70,850 in 2006, an increase of approximately 62% over 2006. Cost of sales in 2007 was $1,307,581 as compared to $211,683 in 2006, an increase of about 518%. Gross profit from the acquired companies amounted to $321,836 in 2007 as compared to $87,706 in 2006, an increase of 267%, and gross profit from business not related to the businesses acquired in 2006 amounted to $97,975 in 2007 as compared to $47,349 in 2006, an increase of 107%.
The Company incurred total operating expenses of approximately $3,116,086 in 2007, as compared to $4,440,273 in 2006. The decrease of operating expenses in the amount of $1,324,187 (or approximately 30%) was primarily contributed by the decrease in the stock based compensation of $1,961,940, which is off-set by an increase of $454,397 in Selling, General and Administrative expenses and an increase of $183,356 in Depreciation and Amortization of Property, Plant and Equipment.
Financing expense for the full year ended December 31, 2007 was approximately $666,063, as compared to $257,861 for the same corresponding period in 2006, an increase of 158%. This increase was due to the interest and intrinsic values of the convertible loans obtained in 2007 in the amount of $805,000 with an interest rate of 10% per annum, as compared to a total of $710,000 convertible loans obtained in 2006 which were all converted to common shares of the Company as at October 31, 2006, mostly within 30 days from the date of each of the loan agreements. The interest amount for the convertible loans totaled $39,621 in 2007 as compared to $25,541 in 2006, an increase of 55%, whereas the expensed intrinsic values of the conversion features of all the convertible loans obtained in 2007 totaled $628,476 as compared to $232,320 for those loans obtained in 2006, an increase of 171%.
For the fiscal year ended December 31, 2007, we recorded a loss from equity investment of RM400,000 (approximately $105,263),our equity investment basis incurred by Synergy Cards Sdn. Bhd., a company in Malaysia which we have a 20% equity stake as at December 31, 2007. Synergy card has incurred losses since inception however our losses are limited to our investment Synergy Cards, incorporated in late 2005, has obtained the approval from the Central Bank of Malaysia in the middle of 2006 to conduct the credit card business under the Payment Systems Act. It has also obtained the licenses from both MasterCard Worldwide and Visa International to issue its credit cards using such brands. Currently, it is in its final stages of preparation for the launch of its credit card business.
Net loss for the year ended December 31, 2007 was $3,098,535 as compared to $4,892,464 for the year ended December 31, 2006, a reduction in net loss of $1,793,929 (or approximately 37%). This decrease was mainly due to an increase in revenue (and hence gross profit) and a reduction in operating expenses.
I'm looking forward as well! Almost all of the insider buys have been at prices higher than the current market price. While the chart could look a bit better, I'm hoping this combined with some great fundamentals will launch this into a sustained uptrend.
Thanks for the PM earlier.
GLTU,
Murocman
Ken,
Appreciate the feedback & thanks. I realize I'm in a potential quagmire here as there is lots of overhead resistance.
The huge insider buying and prospect of significantly improved fundamentals made it worth the risk for me. That said, will keep a close eye and get out quickly if things don't pan out to the upside.
Thanks again,
Murocman
CDTR.OB: $2,691,976 of net insider buying since 12/07, at prices ranging from $0.05 to $0.23. Float is 27M. 10K due this week. Do your DD. All signs point to good things to come!
GLTA,
Murocman
CDTR.OB: $2,691,976 of net insider buying since 12/07, at prices ranging from $0.05 to $0.23. Float is 27M. 10K due this week. Do your DD. All signs point to good things to come!
GLTA,
Murocman
CDTR.OB: $2,691,976 of net insider buying since 12/07, at prices ranging from $0.05 to $0.23. Float is 27M. 10K due this week. Do your DD. All signs point to good things to come!
GLTA,
Murocman
CDTR.OB: $2,691,976 of net insider buying since 12/07, at prices ranging from $0.05 to $0.23. Float is 27M. 10K due this week. Do your DD. All signs point to good things to come!
GLTA,
Murocman
CDTR.OB: $2,691,976 of net insider buying since 12/07, at prices ranging from $0.05 to $0.23. Float is 27M. 10K due this week. Do your DD. All signs point to good things to come!
GLTA,
Murocman
$2,691,976 of net insider buying since 12/07, at prices ranging from $0.05 to $0.23. Float is 27M. 10K due this week. All signs point to good things to come!
GLTA,
Murocman
Check out PAOS.OB
$0.02 in earnings and a share price below that
33M shares O/S
Large govt contract that will continue to produce cash flow
Rid of convertible debt and R/S requirement
Looks like this might be a No Brainer!
GLTA,
Murocman
Check out PAOS.OB
$0.02 in earnings and a share price below that
33M shares O/S
Large govt contract that will continue to produce cash flow
Rid of convertible debt and R/S requirement
Due your DD on this one...looks like it could be a big winner!
GLTA
Murocman
Looks like this might be a big winner!
$0.02 in earnings and a share price below that
33M shares O/S
Large govt contract that will continue to produce cash flow
Rid of convertible debt and R/S requirement
I think it's time to take a starter position!
GLTA,
Murocman
Not necessarily. My understanding is if you change your symbol, you have to change your CUSIP, but the reverse does not necessarily apply. I found the following on the CUSIP Bureau site:
How To Request a CUSIP Number:
From the CUSIP home page (www.cusip.com), select the CUSIP Request link.
Select the appropriate Application (from the left navigation bar) for the type of security for which you are requesting a CUSIP number.
Fill in the form selected for the Offering, providing
Issuer and Issue information
Contact and billing information.
Attach the supporting document(s) directly to the CUSIP Request Form under the section “Offering Documents”.
Click ‘Submit’ button to send your request to the CUSIP Service Bureau for processing.
Upon completion of the CUSIP assignment, an electronic confirmation will be emailed to you. The confirmation will contain the CUSIP number(s) requested, Issuer and Issue descriptions in the standardized CUSIP format and 12-character ISINs, where applicable.
Retain the Request ID number that displays when the request has been successfully completed.
Top ↑
--------------------------------------------------------------------------------
Approximate Turnaround Times*:
Express one-hour turnaround time (50% surcharge over regular fees)
Regular 24-hour turnaround time
* Upon receipt of the completed application and appropriate documentation
Top ↑
Standard Fees for CUSIP Assignment (as of January 1, 2008)
For an offering requiring a single CUSIP, the fee is $138.
For an offering requiring multiple maturities, the fee is $138 for the first CUSIP number and $15 for each additional maturity per series.
For a short-term offering with a maturity of less than one year, the fee is $69.
For non standard CUSIP fees, please contact cusip_comments@standardandpoors.com
Top ↑
How does CUSIP handle special situations?
Corporate Actions: Name Changes/Mergers/Reorganization:
Equity issues (common stock, preferred, rights, etc.) require a new CUSIP number based on the type of the corporate action or if the alphabetical sequencing of the Issuer has changed.
New CUSIPs may be required for debt issues if the debt is listed with the NYSE and a Supplemental Listing Application is filed with the Exchange to list the debt under the new name.
The CUSIP Service Bureau must be notified of any name change that occurs, including mutual funds. Even if the CUSIP is not expected to change, final documentation reflecting the effective date of the action is required as all name changes need to be accurately reflected in the CUSIP database.
It looks to me like this should happen very quickly if the company has all of its documents together. If UHCR did in fact submit this last week, and the change has not occurred, then there must be some problem with their documentation.
The other possibility, is that they said they were going to do this, and haven't actually gotten around to it yet. That's the problem in Pinkland....no transparency because they are not required to file with the SEC.
Hope this helps?
Murocman
I just watched ONMC (Omninet)/AQUI Aquagold go through it and it took almost a month.
Right. But if you go look at what it is now (which I posted earlier), and continue to check, you will see when the new one shows up. I realize that requires a bit of work and record keeping, but what do you want for free?
You have to create your own. It's free.
So what's the connection, if any with Liquid Blue? I would think that if Liquid Blue was going to go public via R/M in to this shell, that their existing management would be the ones running the show?
The background of this CEO does not give me any warm fuzzy that Liquid Blue is in any way involved in this transaction.
Please enlighten.....
Thanks.
Murocman
A website to monitor for CUSIP changes:
The CUSIP bureau website can be found at:
https://www.isin.cusip.com/
UHCR's current CUSIP is per a search is:
904049103
Any will have to show up there.
GLTA,
Murocman
$0.03x5000 - $0.04x5000
You hit the nail on the head...revenues, earnings, sales volume and thrid party verification of deals will bring the big money in and make for a sustained run IMO.
GLTA,
Murocman
These releases need to contain numbers of cases, sales amounts and verification by the purchaser, or they lack credibility.
Not getting back in this until this happens.
GLTA,
Murocman
was 5x.03, 5x.04 as of market close Friday
CDTR has had significant insider buying in the last couple months:
http://www.secform4.com/insider-trading/1085113.htm
10Q is due out Monday. NT-Q was filed Friday saying it was delayed. The same thing was done back in November, and the company still filed on time.
Could be an explosive play. Company is an Asian debit/credit card processor. Earnings report for third quarter was pretty good and looks like things are headed in the right direction.
GLTA,
Murocman
Cardtrend filed NT-Q in Nov 07 but still filed on time. The reasons were the same.
Maybe we will still get the report on Monday. If not, I bet we get it by the end of the week.
Made a significant bet here based on all the insider buying. That is usually a very bullish leading signal.
GLTA,
John
Good article. Looks like this has promise. Hopefully the company can execute on the business end to generate some mass appeal?
The only thing I can think of is that there may have been some clause that if they missed a payment, that the loan immediately became callable?
That's what still bugs me about all of this. I agree that sometimes you have to take out loans, but if the business is working I'm thinking they should have had the revenue to cover the debt obligation(s)given the B&D royalties/sales. That said, if they didn't get paid for what they sold to Sharper Image, they could have easily ended up in a cash flow crunch.
All should be answered here by the end of the month when the 10Q is due. I'm hoping it says that they have put their problems behind and will become cash flow positive going forward.
At this point, I'll wait and watch until I see some positive progress before getting back on board.
GLTU,
Murocman
While you may be right, the fact that insiders have bought 22,556,500 shares since Oct 07 (some at much higher prices than where we are today) leads me to believe that they think the price is going to go much, much higher.
Murocman